Literature DB >> 26775360

The 16, 18, and 45 HPV infection in high grade squamous cervical lesions in primary hr-HPV test screening program.

C Chiappetta, E Lendaro, J Cacciotti, R Zaralli, C Puggioni, G Migliore, V Petrozza, C Della Rocca, C Di Cristofano.   

Abstract

Infection with high-risk human papillomavirus (hr-HPV) 16, 18, and 45 causes 94% of cervical carcinoma. In the present screening center the authors perform the hr-HPV test followed by Pap test to women aged 35-64 years if they result hr-HPV+. The authors' aimed to provide data regarding the genotyping test and eventually to propose this test as alternative to triage cytology. They used a genotyping test to identify HPV 16, 18, and 45 in 22 women with histological diagnosis of CIN2+, 22 women with histological diagnosis of CIN1 and 22 women hr-HPV+/Pap-. The group of CIN2+ showed the higher positivity to the test and the higher positivity to HPV 16 than other groups. Analyzing the clinical performance of the genotyping test the authors observed that the specificity was 64%. From these data they concluded that the identification of HPV 16 is predictive for high-grade lesions but this test could not be used alternatively to triage cytology.

Entities:  

Mesh:

Year:  2015        PMID: 26775360

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  2 in total

1.  Evaluation of the management of Hr-HPV+/PapTest- women: results at 1-year recall.

Authors:  Caterina Chiappetta; Chiara Puggioni; Eugenio Lendaro; Jessica Cacciotti; Roberto Zaralli; Giovanna Migliore; Paola Bellardini; Vincenzo Petrozza; Carlo Della Rocca; Claudio Di Cristofano
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

2.  Analysis of ROC: The value of HPV16 E6 protein in the diagnosis of early stage cervical carcinoma and precancerous lesions.

Authors:  Li Sun; Shubin Xu; Lei Liang; Liang Zhao; Lei Zhang
Journal:  Oncol Lett       Date:  2016-07-11       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.